BOSTON ( TheStreet) -- Last January, I invited my Twitter followers to make their own biotech stock predictions for 2013. Let's check in to see whose crystal ball was in fine working order.
AMRN - still independent, launch sales - they will spend much more on mkting, admin, sales than actual gains from product sales. No NCE/— Sport234a2b (@Sport234a) January 1, 2013
Amarin (AMRN) has been a big loser, which makes @Sport234a2b a big winner!
Nope, but Targacept (TRGT) is up almost 30% this year despite, basically, doing nothing. TRGT data by YCharts
@ adamfeuerstein my wildest prediction: $CYTK breaks thru $1. benefit in ALS+partner.meets 1ary endpnt in HF— Juan P. Serrate, DVM (@JPZaragoza1) January 1, 2013Cytokinetics (CYTK) closed Friday at $8.18, so you got that right, even after factoring in the 1-for-6 reverse stock split. No ALS data or partner yet and that heart-failure drug isn't looking so hot.
@ adamfeuerstein Amrn BO price $23 by April— mimosttr (@trstmomi) January 2, 2013Fail.
SRPT - expect FDAyes 4 a NDA filing based on current data, a very tough panel review potential late 13, very volatile stk in 13.— Sport234a2b (@Sport234a) January 1, 2013Sarepta Therapeutics (SRPT - Get Report) a volatile stock? You betcha. We're still waiting for the actual eteplrisen filing and expected FDA panel, which are now 2014 events.
@ adamfeuerstein $GSK will buy the rest of $FOLD 5-6 range. $INCY will be bid for by several BP's making it the star of the year.— JNV (@JNVcapital) January 1, 2013Amicus Therapeutics (FOLD) and Incyte (INCY) are still single.
@ adamfeuerstein $SGMO and other HIV-elimination (cure) technologies emerge as a threat to $GILD $JNJ $MRK $GSK and others— Martin Shkreli (@MartinShkreli) January 1, 2013Martin was kidding, I hope.
.@ adamfeuerstein Mdvn pre-chemo data trumps zytiga by 2 months. Combo trials gives PCA patients an extra 8 months (2014 data?). Dndn dies.— daviesbj (@daviesbj) January 1, 2013I hesitate to congratulate Ben for his prescient prediction because it will only swell his already-robust ego.
@ adamfeuerstein APPA is the best performer out of all of the he "A" stocks(AMRN, ARNA, ALXA have TERRIBLE launches and stock prices suffer)— Chet Stedman (@ChetStedman5) January 1, 2013A.P. Pharma (APPA) is not enjoying 2013: APPA data by YCharts
But yes, the "A" drug launches pretty much suck, so good on 'ya!
@ adamfeuerstein Mnkd will be the biotech of the year.— Al Marino (@optiontrader78) January 1, 2013MannKind (MNKD) the stock of the year? Not a chance, but shares are up 146% so you get half credit.
@ adamfeuerstein I predict the anti-PD1s will be big successes in multiple solid tumor types. Lung and melanoma in particular. $BMY and $MRK— Chris Ahlstrand (@ahlstrac) January 1, 2013Excellent. You were spot on.
@ adamfeuerstein I predict you are accused of being a hedge fund shill at least 500x in 2013— Stock Jock (@hedgeorbehedged) January 1, 2013Too easy.
@ adamfeuerstein Some speculative predictions: ACHN does a deal w/ABT or JNJ for 3102. 1625 remains unpartnered.— John Alan Tucker (@JohnTuckerPhD) January 1, 2013Nope. Very little hepatitis C deal-making this year, but Achillion Pharma's (ACHN) sovaprevir ('1625) remains unpartnered. Correct.
@ adamfeuerstein celgene? Most undervalued mega biotech on the market? I only play with options though— SAmitBhatt (@SamitBhatt) January 1, 2013Let's take a look at the year-to-date stock performance of the big-cap biotechs: CELG data by YCharts
Celgene (CELG - Get Report)... Booyah!
@ adamfeuerstein I share your healthy skepticism for Arena Pharmaceuticals but I predict their launch of Belviq will not be a disaster.— Matthew C. MacIsaac (@macissm) January 1, 2013Arena Pharma's (ARNA - Get Report) Belviq launch has been a near disaster. Half credit.
@ adamfeuerstein $AMRN no b/o but partnership deal. $VICL primary endpoint misses but overall survival data +. $SRPT accelerated approval.— Bobby Shea (@robertcshea) January 1, 2013O-fer. Better luck next year.
@ adamfeuerstein big year for $OPK diagnostics platforms— Raymond Gachette (@raygachette) January 1, 2013I don't know what Opko Health (OPK) actually did this year to validate its diagnostics business, but the stock worked. OPK data by YCharts
@ adamfeuerstein prediction both ARNA and vvus fail miserably and their stocks trade for the cash on b.s. by yr end— Rafa (@coffee_junkies) January 1, 2013Congrats. Well done.
@ adamfeuerstein Envouraged by the positive performance of new IPOs, biotechs start reconsidering going public as a viable exit— Vikram Khanna (@VikramKhanna_) January 1, 2013Vikram wins best prediction of 2013.
@ adamfeuerstein General: 2013 could be record year for sector M,P(partnerships)&A.— Mike Huckman (@MikeHuckman) January 1, 2013It has been a good year for deal making, maybe not as much as M&A as you predicted however.
@ adamfeuerstein $SGMO hits one target after another,becoming the gene therapy platform of choice: lot of headache for many pharma firms— Ralph (@StuckInStock) January 1, 2013The chart says: "Incorrect!" SGMO data by YCharts
@ adamfeuerstein based on upcoming catalysts, I think it's possible, with multiple + data scenarios, $ANAC sees new highs in 2013— TheEscapeGroup (@TheEscapeGroup) January 1, 2013Nice call on Anacor Pharma (ANAC), but it does illustrate some of the absurd stock moves during this year's biotech bubble. ANAC data by YCharts
@ adamfeuerstein big year for srpt and Aegr. Srpt gets accelerated approval. Aegr gets emea approval. FDA rejects Isis.— Joe Smith (@zwerp2000) January 1, 2013
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Check Out Our Best Services for Investors
Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.